|
22/02/2012
|
|
CORRECTION: Filgrastim Fails to Improve Ischemic Stroke Outcomes
|
|
A story titled “Filgrastim Fails to Improve Ischemic Stroke Outcomes,” published February 21, 2012, misstated the phase of the AXIS 2 trial. It was a phase II trial.
|
|
|
22/02/2012
|
|
Filgrastim Fails to Improve Ischemic Stroke Outcomes
|
|
NEW ORLEANS (EGMN) –A granulocyte colony-stimulating drug did not protect brain tissue or improve functional outcomes after ischemic stroke.Researchers had high hopes for filgrastim, which is approved...
|
|
|
22/02/2012
|
|
Topical Cyclosporine Proves Beneficial For Ocular Rosacea
|
|
WAIKOLOA, HAWAII (EGMN) – Topical cyclosporine 0.05% ophthalmic emulsion significantly outperformed artificial tears for the treatment of ocular rosacea in a double-blind, randomized, multicenter stud...
|
|
|
21/02/2012
|
|
The Oncology Report Guide to Cancer Drugs and Devices in 2011
|
|
NEW DRUG APPROVALS• Abiraterone acetate (Zytiga Tablets, Centocor Ortho Biotech, Inc.). An androgen suppressant that decreases testosterone production for use in combination with prednisone for the tr...
|
|
|
17/02/2012
|
|
NICE Decision on Erlotinib to Hinge on Cost Comparison With Gefitinib
|
|
The cost-effectiveness agency for England and Wales has issued new draft guidance saying that it is not yet able to recommend erlotinib for the first-line treatment of advanced or metastatic EFGR muta...
|
|
|
16/02/2012
|
|
Prophylactic Semuloparin Cuts Rate of VTE in Cancer Patients
|
|
Semuloparin, an ultralow-molecular-weight heparin, reduced the incidence of venous thromboembolic events when given prophylactically to patients with a variety of metastatic or locally advanced solid ...
|
|
|
14/02/2012
|
|
Everolimus Shrinks Angiomyolipomas from Tuberous Sclerosis Complex
|
|
SAN FRANCISCO (EGMN)–Everolimus is efficacious and safe for shrinking renal angiomyolipomas and reducing the formation of new ones in patients having the genetic disorder tuberous sclerosis complex or...
|
|
|
10/02/2012
|
|
FDA Panel Nixes Decitabine for Acute Myeloid Leukemia
|
|
SILVER SPRING, MARYLAND (EGMN) – The leukemia drug decitabine didn’t show robust-enough results to convince the majority of an advisory panel to support its approval by the U.S. Food and Drug Administ...
|
|
|
09/02/2012
|
|
U.S. Agency Rejects Denosumab Against Bone Metastasis in Prostate Cancer
|
|
SILVER SPRING, MD. (EGMN) – A U.S. Food and Drug Administration advisory panel voted 12 to 1 on Feb. 8 that denosumab did not have a favorable risk-benefit profile as a treatment to reduce the risk of...
|
|
|
08/02/2012
|
|
FDA Questions Earlier Denosumab Use in Prostate Cancer
|
|
The Food and Drug Administration questions whether an additional indication for denosumab to delay bone metastases in men with castrate-resistant prostate cancer who are at high risk for such metastas...
|
|
|
08/02/2012
|
|
Kidney Cancer Patients May Need Higher Axitinib Dose
|
|
SAN FRANCISCO (EGMN)–Some patients with metastatic renal cell carcinoma may need a higher-than-standard dose of the newly approved antiangiogenic agent axitinib to achieve optimal benefit, according t...
|
|
|
07/02/2012
|
|
Breast Cancer Drug Exemestane Linked to BMD Loss
|
|
Exemestane significantly decreases bone mineral density in healthy postmenopausal women who take it to reduce their risk of breast cancer, according to a study published online Feb. 7 in The Lancet On...
|
|
|
07/02/2012
|
|
ALSYMPCA Trial: Radium-223 Prolongs Life in Some Prostate Cancers
|
|
SAN FRANCISCO (EGMN) – Radium-223 chloride, the first alpha particle–emitting bone-targeted agent, is efficacious and safe for treating men with bone metastases of castration-resistant prostate cancer...
|
|
|
04/02/2012
|
|
MDV3100 Cuts Risk of Death in Advanced Prostate Cancer
|
|
SAN FRANCISCO (EGMN) – MDV3100, new oral inhibitor of androgen receptor signaling, reduces the risk of death by more than a third after a failure of docetaxel chemotherapy in men with progressive cast...
|
|
|
03/02/2012
|
|
Intracranial Bleed Risk Higher in Warfarin Than Rivaroxaban Users
|
|
NEW ORLEANS (EGMN) – Compared with warfarin, the new-generation anticoagulant rivaroxaban was associated with a 40% lower risk of intracranial hemorrhage in patients with atrial fibrillation who were ...
|
|
|
02/02/2012
|
|
GAD-alum Antigen Therapy Fails to Halt Progression of Type 1 Diabetes
|
|
Antigen therapy with glutamic acid decarboxylase 65 formulated with alum failed to induce immunologic tolerance and stem the loss of stimulated serum C-peptide in a phase III clinical trial of new-ons...
|
|
|
01/02/2012
|
|
ASCO GU to Spotlight Prostate Cancer Drugs MDV3100 and Radium-223
|
|
The 2012 Genitourinary Cancers Symposium, to be held Feb. 2-4, will feature potentially practice-changing data on two novel agents – MDV3100 and radium-223 chloride – in prostate cancer.• Results of t...
|
|
|
01/02/2012
|
|
CORRECTION: U.S. Agency Approves Linagliptin/Metformin Combo For Type 2 Diabetes
|
|
An article titled “U.S. Agency Approves Linagliptin/Metformin Combo For Type 2 Diabetes,” published January 31, 2012, misstated the approval date of the linagliptin/metformin tablet. It was approved J...
|
|
|
01/02/2012
|
|
U.S. Agency Approves Linagliptin/Metformin Combo For Type 2 Diabetes
|
|
The U.S. Food and Drug Administration on Jan. 31 approved a type 2 diabetes therapy that combines linagliptin and metformin in a single tablet taken twice daily.The approval was announced by Eli Lilly...
|
|
|
31/01/2012
|
|
Vismodegib Receives FDA Approval for Metastatic BCC
|
|
The Food and Drug Administration has approved vismodegib, an oral, once-daily medication for adults with locally advanced and metastatic advanced basal cell carcinoma on Jan. 30.Vismodegib (Erivedge) ...
|
|
| |